Fortress Biotech, Inc. (FBIO) shareholders
FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
$1.88−0.11 (-5.53%)
Close on Nov 13, 2026Market cap $69.14MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
17.5%
6M of 33M shares
Institutional holders
55
13 new, 10 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lindsay A. Rosenwald, M.D. | 6,917,715 | 20.70% | 13D (active) amendment | Mar 18, 2026 |
| Highbridge Capital Management, LLC | 2,734,654 | 7.80% | 13G (passive) amendment | Mar 31, 2026 |
| Israel A. Englander Joint filing with Millennium Management LLC (6.50%), Millennium Group Management LLC (6.50%) and 1 more | 2,165,401 | 6.50% | 13G (passive) amendment | Sep 30, 2026 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.30%), Israel A. Englander (5.30%) and 1 more | 1,778,561 | 5.30% | 13G (passive) | Aug 26, 2026 |
| Michael S. Weiss | 1,130,520 | 7.60% | 13D (active) amendment | Nov 14, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FBIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,037,203 | 3.11% | $3.17M | +71,173 | 0.00% |
| Opaleye Management Inc. | 890,000 | 2.67% | $2.72M | −152,000 | 0.25% |
| Mackenzie Financial Corp | 555,676 | 1.67% | $1.70M | New | 0.00% |
| Gsa Capital Partners Llp | 458,472 | 1.37% | $1.40M | +204,338 | 0.09% |
| Shikiar Asset Management Inc | 305,469 | 0.92% | $935.00K | – | 0.24% |
| Geode Capital Management, LLC | 300,521 | 0.90% | $919.94K | +10,266 | 0.00% |
| BlackRock, Inc. | 224,782 | 0.67% | $687.83K | +27,697 | 0.00% |
| Two Sigma Investments, LP | 213,786 | 0.64% | $654.19K | +16,961 | 0.00% |
| Bridgeway Capital Management, LLC | 177,368 | 0.53% | $542.75K | −5,000 | 0.01% |
| Vanguard Fiduciary Trust Co | 166,371 | 0.50% | $509.10K | +23,836 | 0.00% |
| HB Wealth Management, LLC | 116,675 | 0.35% | $357.03K | −3,500 | 0.00% |
| Kestra Advisory Services, LLC | 116,235 | 0.35% | $355.68K | −13,566 | 0.00% |
| Acadian Asset Management LLC | 107,303 | 0.32% | $327.00K | +66,853 | 0.00% |
| State Street Corp | 101,601 | 0.30% | $310.90K | – | 0.00% |
| Goldman Sachs Group Inc | 96,358 | 0.29% | $294.86K | New | 0.00% |
| Integrated Wealth Concepts LLC | 90,400 | 0.27% | $276.62K | +45,200 | 0.00% |
| Renaissance Technologies LLC | 86,390 | 0.26% | $264.35K | −13,200 | 0.00% |
| Citadel Advisors LLC | 77,065 | 0.23% | $235.82K | −103,224 | 0.00% |
| Integrated Quantitative Investments LLC | 68,692 | 0.21% | $210.20K | New | 0.03% |
| Panagora Asset Management Inc | 66,025 | 0.20% | $202.04K | +9,357 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 55 | 6M | 17.5% | 13 / 13 | 18 / 10 | 1M | 1M |
| Q1 2026 | 52 | 5M | 16.1% | 13 / 11 | 17 / 11 | 2M | 1M |
| Q4 2025 | 52 | 6M | 17.7% | 13 / 16 | 15 / 15 | 2M | 1M |
| Q3 2025 | 56 | 4M | 13.4% | 20 / 16 | 13 / 13 | 1M | 2M |
| Q2 2025 | 49 | 5M | 14.9% | 11 / 16 | 12 / 8 | 2M | 2M |
| Q1 2025 | 46 | 5M | 14.7% | 2 / 19 | 11 / 9 | 1M | 1M |
| Q4 2024 | 53 | 5M | 14.4% | 11 / 22 | 12 / 8 | 1M | 1M |
| Q3 2024 | 50 | 4M | 13.3% | 6 / 22 | 12 / 5 | 1M | 1M |
| Q2 2024 | 50 | 4M | 11.3% | 16 / 15 | 8 / 5 | 1M | 0M |
| Q1 2024 | 39 | 3M | 8.4% | 8 / 12 | 10 / 10 | 1M | 3M |
| Q4 2023 | 42 | 5M | 15.2% | 41 / 1 | 0 / 1 | 5M | 0M |
| Q3 2023 | 2 | 0M | 0.5% | 2 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
15 funds held FBIO in Q2 2026, 72% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of FBIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 697,802 | 2.09% | $2.14M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 279,891 | 0.84% | $856.47K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Fund | 152,368 | 0.46% | $466.25K | 0.47% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 131,019 | 0.39% | $366.85K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 88,143 | 0.26% | $269.72K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 49,359 | 0.15% | $138.21K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 35,874 | 0.11% | $100.45K | 0.00% | May 31, 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 25,000 | 0.07% | $76.50K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 20,365 | 0.06% | $57.02K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 18,051 | 0.05% | $55.24K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 10,255 | 0.03% | $31.38K | 0.00% | Jun 30, 2026 |
| Nomura Healthcare Fund | 6,666 | 0.02% | $20.40K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 5,933 | 0.02% | $18.15K | 0.01% | Jun 30, 2026 |
| Total Stock Market Index Trust | 728 | 0.00% | $2.23K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 20 | 0.00% | $61 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael S. Weiss | Executive Vice Chairman, Director | 2,276,562 | 6.83% | Mar 20, 2026 |
| Lindsay A. Rosenwald Md | PRESIDENT, CEO & CHAIRMAN, Director, 10% owner | 6,954,507 | 20.85% | Mar 20, 2026 |
| David Jin | Chief Financial Officer | 1,652,761 | 4.96% | Oct 1, 2026 |
| J. Jay Lobell | Director | 192,397 | 0.58% | Jan 5, 2026 |
| Jimmie Harvey | Director | 146,704 | 0.44% | Jan 5, 2026 |
| Dov Klein | Director | 131,905 | 0.40% | Jan 5, 2026 |
| Kevin Lorenz | Director | 101,675 | 0.30% | Jan 5, 2026 |
| Malcolm Hoenlein | Director | 115,747 | 0.35% | Jan 5, 2026 |
| Lucy Lu | Director | 61,273 | 0.18% | Jan 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Jin Chief Financial Officer | Oct 1, 2026 | Award | +1,190 | $1.82 | $2.16K | 1,652,761 |
| David Jin Chief Financial Officer | Jun 22, 2026 | Award | +400,000 | – | – | 1,651,571 |
| David Jin Chief Financial Officer | Apr 1, 2026 | Award | +2,967 | $2.18 | $6.47K | 1,251,571 |
| Lindsay A. Rosenwald Md PRESIDENT, CEO & CHAIRMAN, Director, 10% owner | Mar 18, 2026 | Award | +475,424 | – | – | 4,586,841 |
| Michael S. Weiss Executive Vice Chairman, Director | Mar 18, 2026 | Award | +475,424 | – | – | 2,276,562 |
| Jimmie Harvey Director | Jan 1, 2026 | Award | +27,322 | – | – | 146,704 |
| Dov Klein Director | Jan 1, 2026 | Award | +27,322 | – | – | 130,105 |
| J. Jay Lobell Director | Jan 1, 2026 | Award | +27,322 | – | – | 192,397 |
| Malcolm Hoenlein Director | Jan 1, 2026 | Award | +27,322 | – | – | 115,747 |
| Kevin Lorenz Director | Jan 1, 2026 | Award | +27,322 | – | – | 101,009 |
| David Jin Chief Financial Officer | Oct 1, 2025 | Award | +2,711 | $1.31 | $3.55K | 1,248,604 |
| David Jin Chief Financial Officer | Apr 1, 2025 | Award | +5,000 | $1.22 | $6.10K | 1,245,893 |
| Lindsay A. Rosenwald Md PRESIDENT, CEO & CHAIRMAN, Director, 10% owner | Jan 1, 2025 | Award | +454,153 | – | – | 4,111,417 |
| J. Jay Lobell Director | Jan 1, 2025 | Award | +49,383 | – | – | 165,075 |
| Dov Klein Director | Jan 1, 2025 | Award | +49,383 | – | – | 102,783 |
| Malcolm Hoenlein Director | Jan 1, 2025 | Award | +49,383 | – | – | 88,425 |
| Jimmie Harvey Director | Jan 1, 2025 | Award | +49,383 | – | – | 119,382 |
| Michael S. Weiss Executive Vice Chairman, Director | Jan 1, 2025 | Award | +454,153 | – | – | 1,801,138 |
| Kevin Lorenz Director | Jan 1, 2025 | Award | +49,383 | – | – | 73,687 |
| Lucy Lu Director | Jan 1, 2025 | Award | +49,383 | – | – | 61,273 |
| David Jin Chief Financial Officer | Dec 19, 2024 | Award | +1,000,000 | – | – | 1,240,893 |
| David Jin Chief Financial Officer | Oct 1, 2024 | Award | +2,625 | $1.23 | $3.23K | 240,893 |
| Lindsay A. Rosenwald Md PRESIDENT, CEO & CHAIRMAN, Director, 10% owner | Sep 23, 2024 | Buy | +763,359 | $1.84 | $1.40M | 3,657,264 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Jul 11, 2024 | Buy | +5,000 | $7.48 | $37.40K | 127,500 |
| David Jin Chief Financial Officer | Jul 10, 2024 | Buy | +500 | $7.50 | $3.75K | 500 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Jul 9, 2024 | Buy | +5,000 | $7.39 | $36.95K | 122,500 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Jul 8, 2024 | Buy | +5,000 | $7.35 | $36.75K | 117,500 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Jun 28, 2024 | Buy | +20,000 | $1.64 | $32.80K | 2,893,905 |
| Dov Klein Director | May 20, 2024 | Sale | −10,000 | $1.89 | $18.90K | 53,400 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | May 16, 2024 | Buy | +10,000 | $1.76 | $17.60K | 2,873,905 |
| David Jin Chief Financial Officer | Apr 1, 2024 | Award | +2,352 | $1.70 | $4.00K | 238,268 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Jan 5, 2024 | Buy | +50,000 | $2.38 | $119.00K | 2,863,905 |
| Lucy Lu Director | Jan 1, 2024 | Award | +3,333 | – | – | 11,890 |
| Dov Klein Director | Jan 1, 2024 | Award | +6,666 | – | – | 63,400 |
| Malcolm Hoenlein Director | Jan 1, 2024 | Award | +3,333 | – | – | 39,042 |
| J. Jay Lobell Director | Jan 1, 2024 | Award | +6,666 | – | – | 115,692 |
| Michael S. Weiss See Remarks, Director, 10% owner | Jan 1, 2024 | Award | +216,465 | – | – | 1,346,985 |
| Eric K. Rowinsky Director | Jan 1, 2024 | Award | +6,666 | – | – | 68,797 |
| Kevin Lorenz Director | Jan 1, 2024 | Award | +3,333 | – | – | 24,304 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Jan 1, 2024 | Award | +216,465 | – | – | 2,813,905 |
| Jimmie Harvey Director | Jan 1, 2024 | Award | +6,666 | – | – | 69,999 |
| David Jin Chief Financial Officer | Dec 20, 2023 | Award | +140,000 | – | – | 235,916 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Nov 14, 2023 | Buy | +1,567,515 | $1.70 | $2.66M | 2,597,440 |
| Michael S. Weiss See Remarks, Director | Nov 14, 2023 | Buy | +147,058 | $1.70 | $250.00K | 1,130,520 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Sep 26, 2023 | Buy | +100,000 | $0.28 | $28.00K | 15,449,091 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Aug 18, 2023 | Buy | +10,000 | $9.34 | $93.40K | 112,500 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Aug 17, 2023 | Buy | +10,000 | $11.75 | $117.50K | 102,500 |
| Michael S. Weiss See Remarks, Director, 10% owner | Feb 10, 2023 | Buy | +1,197,604 | $0.84 | $1.01M | 14,752,034 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Feb 10, 2023 | Buy | +2,395,209 | $0.84 | $2.01M | 15,349,091 |
| David Jin Chief Financial Officer | Feb 10, 2023 | Buy | +35,928 | $0.84 | $30.18K | 1,438,757 |
| J. Jay Lobell Director | Feb 10, 2023 | Buy | +299,401 | $0.84 | $251.50K | 1,635,401 |
| Eric K. Rowinsky Director | Feb 10, 2023 | Buy | +11,976 | $0.84 | $10.06K | 931,976 |
| Lucy Lu Director | Feb 10, 2023 | Buy | +11,976 | $0.84 | $10.06K | 133,379 |
| Dov Klein Director | Jan 1, 2023 | Award | +100,000 | – | – | 851,015 |
| Lindsay A. Rosenwald Md President, CEO & Chairman, Director, 10% owner | Jan 1, 2023 | Award | +1,219,294 | – | – | 12,953,882 |
| Kevin Lorenz Director | Jan 1, 2023 | Award | +50,000 | – | – | 314,572 |
| J. Jay Lobell Director | Jan 1, 2023 | Award | +100,000 | – | – | 1,336,000 |
| Lucy Lu Director | Jan 1, 2023 | Award | +50,000 | – | – | 121,403 |
| Jimmie Harvey Director | Jan 1, 2023 | Award | +100,000 | – | – | 950,000 |
| Malcolm Hoenlein Director | Jan 1, 2023 | Award | +50,000 | – | – | 535,636 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
5M shares short
Days to cover
23.6
At 0M shares a day
Change since last report
+2.0%
From 5M shares
Short volume, 20 days
51.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Fortress Biotech's stock actually held short. Settlement fails (shares not delivered on time) peaked at 47,185 shares on Aug 25, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Dov Klein Director | May 17, 2024 | 10,000 | $17.60K | May 20, 2024 | Private Placement |
See a number that looks wrong?